Literature DB >> 17853615

Fluorescence microlymphography: diagnostic potential in lymphedema and basis for the measurement of lymphatic pressure and flow velocity.

A Bollinger1, B R Amann-Vesti.   

Abstract

Fluorescence microlymphography (FML) is an almost atraumatic technique used to visualize the superficial skin network of initial lymphatics through the intact skin of man. Visualization was performed with an incident light fluorescence microscope following subepidermal injection of minute amounts of FITC-dextran 150,000 using microneedles. Emanating from the bright dye depot, the surrounding network of microvessels is filled, documentation performed by photography or video film. In congenital Milroy lymphedema, a lack of microlymphatics (aplasia) is typical while in other primary lymphedemas and in secondary lymphedema after mastectomy or irradiation of proximal lymph nodes, the network remains intact but the depicted area is enlarged. Lymphatic microangiopathy characterized by obliterations of capillary meshes or mesh segments develops in phleboedema with trophic skin changes, progressive systemic sclerosis and Fabry's disease. In lipedema, lymphatic microaneurysms are stained. Microlymphatic pressure may also be measured using FML. For this purpose, glass micropipettes are inserted into the capillaries by means of a micromanipulator and pressure is determined by the servo-nulling technique. Normal subjects produced significantly lower pressure (7.9 +/- 3.4 mmHg) compared to patients with primary lymphedema (15.0 +/- 5.1 mmHg, p<0.001). This characteristic lymphatic hypertension may be improved by complex physiotherapy or local application of prostaglandins. Additionally, a modification of the FML procedure can be used to measure lymphatic capillary flow velocity in controls and patients. FML is suited to confirm the clinical diagnosis of lymphedema, contributes to distinguish among various forms of edema, and is useful in clinical research. In addition, FML has also become a tool for experimental animal studies including the depiction of gastric microlymphatics, the measurement of flow velocity in the naked mouse tail, and in evaluation of lymphangiogenesis in a model of Milroy disease.

Entities:  

Mesh:

Year:  2007        PMID: 17853615

Source DB:  PubMed          Journal:  Lymphology        ISSN: 0024-7766            Impact factor:   1.286


  8 in total

Review 1.  Rare adipose disorders (RADs) masquerading as obesity.

Authors:  Karen L Herbst
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

Review 2.  Advances in fluorescent-image guided surgery.

Authors:  Mark J Landau; Daniel J Gould; Ketan M Patel
Journal:  Ann Transl Med       Date:  2016-10

3.  Lipedema and the Evolution to Lymphedema With the Progression of Obesity.

Authors:  Lívia Maria Pereira de Godoy; Henrique Jose Pereira de Godoy; Paula Pereira de Godoy Capeletto; Maria de Fatima Guerreiro Godoy; Jose Maria Pereira de Godoy
Journal:  Cureus       Date:  2020-12-02

Review 4.  Lipedema-Pathogenesis, Diagnosis, and Treatment Options.

Authors:  Philipp Kruppa; Iakovos Georgiou; Niklas Biermann; Lukas Prantl; Peter Klein-Weigel; Mojtaba Ghods
Journal:  Dtsch Arztebl Int       Date:  2020-06-01       Impact factor: 5.594

Review 5.  Emerging lymphatic imaging technologies for mouse and man.

Authors:  Eva M Sevick-Muraca; Sunkuk Kwon; John C Rasmussen
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

6.  From Bench to Bedside: The Role of a Multidisciplinary Approach to Treating Patients with Lymphedema.

Authors:  Rachel Lentz; Christina Shin; Zoe Bloom; Kimiko Yamada; Young-Kwon Hong; Alex K Wong; Ketan Patel
Journal:  Lymphat Res Biol       Date:  2021-02-05       Impact factor: 2.589

7.  OCT-based label-free in vivo lymphangiography within human skin and areola.

Authors:  Utku Baran; Wan Qin; Xiaoli Qi; Goknur Kalkan; Ruikang K Wang
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

Review 8.  Fluorescent Tracers for In Vivo Imaging of Lymphatic Targets.

Authors:  P S Russell; R Velivolu; V E Maldonado Zimbrón; J Hong; I Kavianinia; A J R Hickey; J A Windsor; A R J Phillips
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.